152 related articles for article (PubMed ID: 33083892)
1. Factors Associated with Cancer Screening Among Hopi Men.
Batai K; Sanderson PR; Hsu CH; Joshweseoma L; Russell D; Joshweseoma L; Ojeda J; Burhansstipanov L; Brown SR; Ami D; Saboda K; Harris RB
J Cancer Educ; 2022 Aug; 37(4):915-923. PubMed ID: 33083892
[TBL] [Abstract][Full Text] [Related]
2. Body mass index and cancer screening in older American Indian and Alaska Native men.
Muus KJ; Baker-Demaray T; McDonald LR; Ludtke RL; Allery AJ; Bogart TA; Goldberg J; Ramsey SD; Buchwald DS
J Rural Health; 2009; 25(1):104-8. PubMed ID: 19166569
[TBL] [Abstract][Full Text] [Related]
3. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?
Sirovich BE; Schwartz LM; Woloshin S
JAMA; 2003 Mar; 289(11):1414-20. PubMed ID: 12636464
[TBL] [Abstract][Full Text] [Related]
4. Testing for prostate and colorectal cancer: comparison of self-report and medical record audit.
Hall HI; Van Den Eeden SK; Tolsma DD; Rardin K; Thompson T; Hughes Sinclair A; Madlon-Kay DJ; Nadel M
Prev Med; 2004 Jul; 39(1):27-35. PubMed ID: 15207983
[TBL] [Abstract][Full Text] [Related]
5. Cancer Screening on the Hopi Reservation: A Model for Success in a Native American Community.
Brown SR; Joshweseoma L; Saboda K; Sanderson P; Ami D; Harris R
J Community Health; 2015 Dec; 40(6):1165-72. PubMed ID: 26091896
[TBL] [Abstract][Full Text] [Related]
6. Formative Assessment to Improve Cancer Screenings in American Indian Men: Native Patient Navigator and mHealth Texting.
Batai K; Sanderson PR; Joshweseoma L; Burhansstipanov L; Russell D; Joshweseoma L; Hsu CH
Int J Environ Res Public Health; 2022 May; 19(11):. PubMed ID: 35682130
[TBL] [Abstract][Full Text] [Related]
7. Implications of false-positive results for future cancer screenings.
Taksler GB; Keating NL; Rothberg MB
Cancer; 2018 Jun; 124(11):2390-2398. PubMed ID: 29682740
[TBL] [Abstract][Full Text] [Related]
8. Cancer screening in Queensland men.
Carrière P; Baade P; Newman B; Aitken J; Janda M
Med J Aust; 2007 Apr; 186(8):404-7. PubMed ID: 17437394
[TBL] [Abstract][Full Text] [Related]
9. Use of cancer screening services in Greece and associated social factors: results from the nation-wide Hellas Health I survey.
Dimitrakaki C; Boulamatsis D; Mariolis A; Kontodimopoulos N; Niakas D; Tountas Y
Eur J Cancer Prev; 2009 Jun; 18(3):248-57. PubMed ID: 19491613
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the management of positive fecal occult blood tests.
Rao SK; Schilling TF; Sequist TD
J Gen Intern Med; 2009 Mar; 24(3):356-60. PubMed ID: 19130147
[TBL] [Abstract][Full Text] [Related]
11. Trends in colonoscopy and fecal occult blood test use after the introduction of dual screening offers in Germany: Results from a large population-based study, 2003-2016.
Chen C; Stock C; Jansen L; Chang-Claude J; Hoffmeister M; Brenner H
Prev Med; 2019 Jun; 123():333-340. PubMed ID: 30946858
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study.
Bähler C; Brüngger B; Ulyte A; Schwenkglenks M; von Wyl V; Dressel H; Gruebner O; Wei W; Blozik E
BMC Public Health; 2021 Jan; 21(1):23. PubMed ID: 33402140
[TBL] [Abstract][Full Text] [Related]
13. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies.
Inadomi JM; Vijan S; Janz NK; Fagerlin A; Thomas JP; Lin YV; Muñoz R; Lau C; Somsouk M; El-Nachef N; Hayward RA
Arch Intern Med; 2012 Apr; 172(7):575-82. PubMed ID: 22493463
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening.
Church TR; Yeazel MW; Jones RM; Kochevar LK; Watt GD; Mongin SJ; Cordes JE; Engelhard D
J Natl Cancer Inst; 2004 May; 96(10):770-80. PubMed ID: 15150305
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer screening participation: comparisons with mammography and prostate-specific antigen screening.
Lemon S; Zapka J; Puleo E; Luckmann R; Chasan-Taber L
Am J Public Health; 2001 Aug; 91(8):1264-72. PubMed ID: 11499116
[TBL] [Abstract][Full Text] [Related]
17. Colorectal Cancer Screening Among Adults in Zuni Pueblo: Factors Associated with FOBT and Colonoscopy Utilization.
Edwardson N; Cartwright K; Sheche J; Pankratz VS; Kosich M; Kanda D; Leekity S; Mishra SI
J Community Health; 2023 Aug; 48(4):565-575. PubMed ID: 36752868
[TBL] [Abstract][Full Text] [Related]
18. Is the patient activation measure associated with adherence to colonoscopy after a positive fecal occult blood test result?
Azulay R; Valinsky L; Hershkowitz F; Magnezi R
Isr J Health Policy Res; 2018 Dec; 7(1):74. PubMed ID: 30577883
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice.
Collins JF; Lieberman DA; Durbin TE; Weiss DG;
Ann Intern Med; 2005 Jan; 142(2):81-5. PubMed ID: 15657155
[TBL] [Abstract][Full Text] [Related]
20. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
Guo F; Chen C; Schöttker B; Holleczek B; Hoffmeister M; Brenner H
Int J Cancer; 2020 May; 146(9):2423-2432. PubMed ID: 31291471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
